Istituto Clinico Humanitas

Running trials

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Source

• Recruiting

  Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

  NCT07485296· Phase 2· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Phase 2· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Not yet recruiting

  Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson's Disease

  NCT06814782· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer

  NCT06737107· Source

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Source

• Recruiting

  Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

  NCT06626243· Source

• Recruiting

  Robotic Assisted Major Lung Resection in Elderly Patients

  NCT06496386· Source

• Recruiting

  SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective

  NCT06373601· Source

• Not yet recruiting

  Niraparib and Temozolomide in Patients Glioblastoma

  NCT06258018· Phase 1/2· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· Source

• Recruiting

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· Phase 2· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

  NCT06054555· Phase 3· Source

• Recruiting

  Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology

  NCT06041945· Source

• Enrolling by invitation

  Robotic Surgery in Pulmonary Metastasectomy

  NCT06466070· Source

• Active, not recruiting

  First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

  NCT06398743· Source

• Recruiting

  Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

  NCT06805812· Source

• Recruiting

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  NCT05786924· Phase 1/2· Source

• Recruiting

  Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

  NCT04383119· Phase 2· Source

• Active, not recruiting

  A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 mutation

  NCT04964934· Phase 3· Source

• Active, not recruiting

  Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

  NCT04722848· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Source

• Recruiting

  Observational Study on Skeletal Ewing's Sarcoma

  NCT04845893· Source

• Recruiting

  Study on Clinical Features and Outcomes of Breast Sarcoma

  NCT04749446· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Source

• Recruiting

  Registry of Subjects at Risk of Pancreatic Cancer

  NCT04095195· Source

• Recruiting

  Protocol ITANET - Registry

  NCT04282083· Source

• Recruiting

  An Observational Study on Epithelioid Sarcoma

  NCT03099681· Source

• Recruiting

  Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

  NCT02275286· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting
• Sarcoma5 recruiting
• Childhood cancers4 recruiting
• Colorectal cancer4 recruiting
• Gastric and esophageal cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Head and neck cancer2 recruiting
• Melanoma2 recruiting
• Pancreatic cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Source

• Completed

  Immune Microenvironment and Gene Expression Profiling in Mesothelioma

  NCT06581549· Source

• Completed

  AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

  NCT05471245· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Source

• Terminated

  Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

  NCT05630937· Phase 1/2· Source

• Completed

  A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

  NCT04487067· Phase 3· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

  NCT04495621· Phase 1/2· Source

• Completed

  A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis

  NCT04439526· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Withdrawn

  Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin

  NCT03773510· Phase 3· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Source

• Completed

  Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

  NCT03455504· Phase 2· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Source

• Terminated

  Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

  NCT04656262· Phase 3· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source

• Completed

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· Phase 1· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

• Completed

  Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

  NCT02223208· Phase 1/2· Source

• Completed

  Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

  NCT01208766· Phase 3· Source